IGC חוב להון עצמי IGC Pharma

IGC Pharma, Inc. (IGC) generates revenue through the development of cannabinoid-based treatments for Alzheimer's disease and the sale of wellness products. The company implements ESG principles by monitoring raw material purity and reducing harmful emissions. Early-stage drug trials are outsourced to third-party contractors to diversify risk. This market valuation chart for the company on the GURU.Markets platform demonstrates a debt-to-equity ratio of 0.19.

The specifics of strict government regulation regarding cannabinoid distribution require IGC Pharma, Inc. (IGC) to incur significant logistics security costs, which may impact its financing structure. This financial leverage chart compares the company's total liabilities to its equity, allowing investors to assess the business's reliance on borrowed funds and the risk of cash flow gaps during operational scaling.